Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer
AssigneesVirogin Biotech (Shanghai) Ltd, Virogin Biotech Canada Ltd
InventorsJun Ding, Ronghua Zhao, Shah Rahimian, Qian Tan
Life of this patent
Estimating the term…
Abstract
A pharmaceutical combination where a checkpoint inhibitor is combined with a recombinant oncolytic virus and the use of said combination for the treatment of cancer.
Claims20
A pharmaceutical combination containing recombinant oncolytic virus VG2025 and a checkpoint inhibitor, wherein the checkpoint inhibitor is an anti-PD-I antibody or an anti-PD-LI antibody.
A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a pharmaceutical composition containing recombinant oncolytic virus VG2025, the second container comprises at least one dose of a pharmaceutical composition comprising an anti-PD-1 antibody or an anti-PD-LI antibody, and the package insert comprises instructions for treating an individual having cancer using the pharmaceutical composition.
Dependencies are inferred from the claim text.